Madrigal Pharmaceuticals(NASDAQ) MDGL

Market Cap$11.37B

Since IPO (2016)+5,288%

5 Year+465%

1 Year+70%

1 Month-8%

$492.49

-9.95%

-54.39Today

Madrigal Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 493.11	2026-07-30

Madrigal Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.25%	USD 543.35	2026-07-23
1 month	-8.16%	USD 536.95	2026-06-30
3 month	-4.01%	USD 513.72	2026-05-01
Year to date	-15.32%	USD 582.34	2025-12-31
1 year	+70.11%	USD 289.88	2025-07-30
3 year	+140.19%	USD 205.30	2023-07-31
5 year	+464.72%	USD 87.32	2021-07-30
Since inception	+5,287.93%	USD 10.15	2016-07-25

Madrigal Pharmaceuticals Financials at a Glance

Market Cap

$11.37B

Revenue (TTM)

$1.28B

Net Income (TTM)

-$325.10M

EPS (TTM)

-$12.80

P/E Ratio

-38.52

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$492.49

Volume

1,487,716

Open

$505.55

Price

$492.49

Volume

1,487,716

Open

$505.55

Previous Close

$493.11

Daily Range

$447.01 - $510.55

52-Week Range

$298.00 - $615.00

Estimated Earnings Date

Nov 3, 2026

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$492.49

Volume

1,487,716

Open

$505.55

Previous Close

$493.11

Daily Range

$447.01 - $510.55

52-Week Range

$298.00 - $615.00

Estimated Earnings Date

Nov 3, 2026

MDGL News

research scientists drugs pharma biotech

Page 1

MDGL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Madrigal Pharmaceuticals

Madrigal makes a daily pill to help people with a serious liver disease called MASH. This medicine targets fat and scarring in the liver before it leads to organ failure. The company focuses on adult patients who have moderate to advanced liver damage.

What Madrigal Sells

Rezdiffra: An oral, once-daily medicine that targets thyroid hormone receptors in the liver to reduce fat and inflammation; it is the company's only approved product.
MGL-2086: An experimental drug designed to help with weight loss and metabolism in patients with liver disease.
Ervogastat: A pill that works by blocking the storage of fat in the liver to lower inflammation.
siRNA Programs: Research projects that use gene-silencing technology to stop the proteins that cause liver disease from being made.

New Deals and Pipelines

Introduced Rezdiffra to the United States market in April 2024 and launched in Germany in September 2025.
Acquired an exclusive global license for MGL-2086 from CSPC Pharmaceutical Group Limited in July 2025.
Entered an agreement with Pfizer in December 2025 to develop and sell ervogastat.
Partnered with Suzhou Ribo Life Science and Ribocure Pharmaceuticals in February 2026 for six new genetic research programs.
Secured a $500 million credit facility with Blue Owl Capital in July 2025 to fund business operations.

What Makes the Business Different

Madrigal created the first drug approved by both U.S. and European regulators for non-cirrhotic MASH. The company holds patents for its specific dosing and treatment methods that provide legal protection through 2045.

The Recent Numbers

Product revenue reached $958.4 million for the full year 2025.
Quarterly revenue grew to $321.1 million in Q4 2025, up 210.8% from $103.3 million in Q4 2024.
Net loss for Q4 2025 was $58.6 million, an improvement from a $59.4 million loss in Q4 2024.
Market capitalization increased to $13.1 billion in Q4 2025, up 93.1% year-over-year.
Operating cash flow was negative $133.5 million in Q4 2025, compared to negative $104.5 million in Q4 2024.

Bottom Line

Madrigal transitioned from a research-focused firm to a commercial drug provider by launching the first-ever treatment for a common liver disease. The company is now expanding its reach through global partnerships and new technology to maintain its lead in the market.

AI Generated • Apr 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

915

CEO

William J. Sibold, MBA

Website

www.madrigalpharma.com

Headquarters

West Conshohocken, PA 19428, US

MDGL Financials

Key Financial Metrics (TTM)

Gross Margin

91.48%

Operating Margin

-25.13%

Net Income Margin

-25.32%

Return on Equity

-56.65%

Return on Capital

-31.36%

Return on Assets

-26.12%

Earnings Yield

-2.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.37B

Shares Outstanding

23.06M

Volume

1.49M

Avg. Volume

352.22K

Financials (TTM)

Gross Profit

$1.17B

Operating Income

-$322.62M

EBITDA

-$298.76M

Operating Cash Flow

-$197.72M

Capital Expenditure

-$8.57M

Free Cash Flow

-$206.29M

Cash & ST Invst.

$838.75M

Total Debt

$347.75M

Madrigal Pharmaceuticals Performance Analysis

Madrigal Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 180,133,000	N/A
2025	2025-12-31	USD 958,403,000	432.1%

Madrigal Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	35.0%
Q4	2025-12-31	11.8%
Q1	2026-03-31	-3.0%
Q2	2026-06-30	17.0%

Madrigal Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -17.23	17.8%
2023	2023-12-31	USD -19.99	16.0%
2024	2024-12-31	USD -21.90	9.5%
2025	2025-12-31	USD -12.85	-41.3%

Madrigal Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-167.4%
Q4	2025-12-31	49.4%
Q1	2026-03-31	-26.5%
Q2	2026-06-30	38.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$364.25M

+71.2%

Gross Profit

$324.25M

+59.1%

Gross Margin

89.02%

N/A

Market Cap

$11.37B

N/A

Market Cap/Employee

$12.43M

N/A

Employees

915

N/A

Net Income

-$57.94M

-37.0%

EBITDA

-$56.31M

-45.7%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$838.75M

+5.2%

Total Debt

$347.75M

+180.6%

Accounts Receivable

$192.31M

+142.7%

Inventory

$99.39M

+56.5%

Long Term Debt

$346.72M

+182.1%

Short Term Debt

$1.03M

-1.4%

Return on Assets

-26.12%

N/A

Return on Invested Capital

-37.06%

N/A

Free Cash Flow

$19.08M

+140.5%

Operating Cash Flow

$23.33M

+149.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TECHBio-Techne Corporation

TECHBio-Techne Corporation$72.03+0.00%

BMRNBioMarin Pharmaceutical Inc.

BMRNBioMarin Pharmaceutical Inc.$60.58-1.29%

ABVXAbivax S.A.

ABVXAbivax S.A.$124.33+4.62%

BAXBaxter International Inc.

BAXBaxter International Inc.$26.75+7.99%

EXELExelixis, Inc.

EXELExelixis, Inc.$55.97+1.16%

RYTMRhythm Pharmaceuticals, Inc.

RYTMRhythm Pharmaceuticals, Inc.$105.74-0.74%

JAZZJazz Pharmaceuticals plc

JAZZJazz Pharmaceuticals plc$258.38+0.94%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$91.13+0.11%

NVDANvidia

NVDANvidia$195.04+0.03%

MSFTMicrosoft

MSFTMicrosoft$451.10+0.16%

NOKNokia

NOKNokia$9.09+0.08%

AMZNAmazon

AMZNAmazon$235.50+0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.21+0.07%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$26.97+0.37%

Questions About MDGL

What is the current price of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals is trading at $493.11 per share.

What is the 52-week range for Madrigal Pharmaceuticals?

Over the past 52 weeks, Madrigal Pharmaceuticals has traded between $298.00 and $615.00.

How much debt does Madrigal Pharmaceuticals have?

As of the most recent reporting period, Madrigal Pharmaceuticals reported total debt of $347.31M.

How much cash does Madrigal Pharmaceuticals have on hand?

Madrigal Pharmaceuticals reported $232.19M in cash and cash equivalents in its most recent financial results.

What is Madrigal Pharmaceuticals’s dividend yield?

Madrigal Pharmaceuticals does not currently have a dividend yield.

Madrigal Pharmaceuticals(NASDAQ) MDGL

Madrigal Pharmaceuticals Financials at a Glance

MDGL News

3 Under-the-Radar Stocks to Buy and Hold for a Decade

Biotech vs. Pharma: What's the Difference?

How to Invest in SPDR S&P Biotech ETF (XBI)

Why Madrigal Pharmaceuticals Stock Slumped on Tuesday

Madrigal (MDGL) Q2 Revenue Soars 1,313%

Why Madrigal Pharmaceuticals Stock Is Soaring Today

Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

Why Madrigal Pharmaceuticals Stock Is Sinking Today

MDGL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Madrigal Pharmaceuticals

What Madrigal Sells

New Deals and Pipelines

What Makes the Business Different

The Recent Numbers

Bottom Line

MDGL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Madrigal Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MDGL

What is the current price of Madrigal Pharmaceuticals?

What is the 52-week range for Madrigal Pharmaceuticals?

How much debt does Madrigal Pharmaceuticals have?

How much cash does Madrigal Pharmaceuticals have on hand?

What is Madrigal Pharmaceuticals’s dividend yield?

Premium Investing Services